Please note that this product was withdrawn from the Community register of designated orphan medicinal products in September 2017 on request of the sponsor.
On 17 July 2013, orphan designation (EU/3/13/1152) was granted by the European Commission to Merck KGaA, Germany, for (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl)diamidophosphate (also known as TH-302) for the treatment of pancreatic cancer.
The sponsorship was transferred to Chiltern International Limited, United Kingdom, in June 2016.
|Disease / condition||
Treatment of pancreatic cancer
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.